Vincerx Pharma announces workforce reduction of 55%, cost-control measures
Vincerx Pharma (VINC) announced plans to implement cost-controls and explore strategic alternatives to support advancing the Phase 1 study of VIP943, the company’s novel CD123-targeted antibody-drug conjugate developed with the company’s next-generation VersAptx platform. “We believe VIP943 is a highly differentiated and valuable asset, and we remain fully committed to advancing this program,” said Ahmed Hamdy, M.D., Chief Executive Officer. “As we shared in October, the Phase 1 dose-escalation